2024 American Society of Clinical Oncology (ASCO)
Review presentations, oral abstracts, and other information shared by Dana-Farber physician-scientists at the ASCO 2024 Annual Meeting.
The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the prostate cancer clinical updates you need to know from ASCO 2024.
The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the kidney cancer clinical updates you need to know from ASCO 2024.
The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the bladder cancer clinical updates you need to know from ASCO 2024.
Narjust Florez, MD Discusses International Medical Graduate Challenges
1 out of 4 doctors in the United States graduated from international medical schools, yet according to a study presented at ASCO24, these doctors remain victims of discrimination at frequent rates.
NUT Carcinoma may not be as rare as one thought. Jia Luo, MD, of Dana-Farber, shares new efforts to research this type of rare cancer that can grow anywhere in the body, often in the head, neck and lungs.
Kimia Sorouri, MD, MPH Discusses Fertility and Breast Cancer
Study shows most women attempting to conceive after breast cancer treatment can do so and give birth. Dana-Farber's Kimia Sorouri, MD, MPH, discusses the first prospective study with more than 10 years of follow-up that also accounts for conception attempts.
Lung cancer rates in younger adults are rising. Dana-Farber's Narjust Florez, MD discusses research showing that young patients with lung cancer face ample financial toxicity and issues impacting physical, emotional, and functional well-being.
Palliative care physician Richard Leiter, MD, MA, recounts his support of a young patient with end-of-life care and the complexities of communicating with his family.
Telehealth can significantly reduce greenhouse gas emissions from cancer care, with research showing decentralized cancer care and telemedicine can cut emissions 33% compared to traditional in-person visits.
Antibody-drug conjugate plus a checkpoint inhibitor shows a trend toward improved survival in PD-L1-positive hormone receptor-positive, HER2-negative breast cancer.
Kidney cancer research at ASCO24: Final analysis in JAVELIN Renal 101 trial confirms the efficacy and manageable safety profile of avelumab plus axitinib versus sunitinib in patients with advanced kidney cancer. Dana-Farber's Toni Choueiri, MD, explains more.
Kenneth Kehl, MD, MPH Reviews Artificial Intelligence and Genomic Data
Using artificial intelligence to link genomic data to clinical outcomes in cancer care across institutions without compromising protected health information is challenging.
CNS Lymphoma research at ASCO24: Dana-Farber's Lakshmi Nayak, MD, details findings of a pilot study showing a CAR T-cell therapy has shown promise and is safe and well-tolerated in treating patients with relapsed, treatment-resistant CNS lymphoma.
Toni Choueiri, MD Provides Kidney Cancer CLEAR Trial biomarker analysis
Biomarker analysis in the phase 3 CLEAR trial shows biomarkers don't impact the superiority of lenvatinib plus pembrolizumab versus sunitinib as a first-line therapy in patients diagnosed with advanced kidney cancer.
News Releases
- Dana-Farber Researchers Uncover Disparities in Lived Experiences for Patients and Physicians
- Telehealth Can Significantly Reduce Greenhouse Gas Emissions Associated with Cancer Care, Study Finds
- Clinical Trials Show Promise in Treating Central Nervous System Lymphoma, Breast Cancer, and Glioblastoma
Resources
Awards & Honors
-
Janet L. Abrahm receives ASCO Special Award: (published March 27, 2024)
- Margaret A. Shipp, MD received OncLive's Giants in Cancer Care Award
- The Giants of Cancer Care program aims to honor and celebrate the accomplishments of leading researchers and educators whose discoveries have propelled the field and set the groundwork for future advancements. A selection committee of more than 115 esteemed oncologists choose honorees from a range of tumor types and specialized categories. The inductees have been selected by their peers for their remarkable achievements in oncology research and clinical practice.
-
2024 Fellow of the American Society of Clinical Oncology
- Narjust Florez, MD
- Shail Maingi, MD
Dana-Farber presence at ASCO 2024
-
Conducted nearly 30 oral abstract or clinical science symposium presentations
-
Presented more than 55 poster presentations
-
Participated in dozens of additional presentations in education sessions, special sessions or panel sessions